amlodipine has been researched along with Cardiomyopathies in 18 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 9.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 8.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 5.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 4.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| "Hereditary hemochromatosis is a disorder of iron metabolism, which is currently the most prevalent autosomal recessive disorder in the world, with an expression of the homozygous form occurring in approximately 1 in 200 individuals of European descent." | 1.31 | Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. ( Bartfay, WJ; Crowe, S, 2002) |
| "The effect of long-term administration of amlodipine and cilnidipine was examined on the histopathology and 1,4-dihydropyridine (DHP) calcium channel antagonist receptors in the left ventricle of BIO TO-2 hamsters, a model of dilated cardiomyopathy (DCM)." | 1.31 | Improvement in the histopathology of hearts from cardiomyopathic BIO TO-2 hamsters following long-term administration of amlodipine and cilnidipine. ( Hirano, K; Kimura, R; Ohashi, K; Urayama, A; Watanabe, H; Yamada, S, 2000) |
| "Amlodipine treatment slightly but significantly inhibited the enhanced responses in aorta but did not alter the responses in mesenteric arteries." | 1.30 | Effect of prolonged treatment with amlodipine on enhanced vascular contractility in cardiomyopathic hamsters. ( Fukao, M; Hattori, Y; Kanno, M; Kitabatake, A; Okamoto, H; Sakuma, I; Sato, A; Tomioka, H; Watanabe, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Ward, JL | 1 |
| Guillot, E | 1 |
| Domenig, O | 1 |
| Ware, WA | 1 |
| Yuan, L | 1 |
| Mochel, JP | 1 |
| Hohl, M | 1 |
| Lauder, L | 1 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 1 |
| Götzinger, F | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Padhani, ZA | 1 |
| Gangwani, MK | 1 |
| Sadaf, A | 3 |
| Hasan, B | 2 |
| Colan, S | 3 |
| Alvi, N | 3 |
| Das, JK | 2 |
| Morselli, F | 1 |
| Fang, L | 1 |
| Ambrosini, I | 1 |
| Chowienczyk, PJ | 1 |
| Faconti, L | 1 |
| Sohn, JT | 1 |
| Eghbali, A | 1 |
| Kazemi, H | 1 |
| Taherahmadi, H | 1 |
| Ghandi, Y | 1 |
| Rafiei, M | 1 |
| Bagheri, B | 1 |
| Packer, M | 1 |
| Carson, P | 1 |
| Elkayam, U | 1 |
| Konstam, MA | 1 |
| Moe, G | 1 |
| O'Connor, C | 1 |
| Rouleau, JL | 1 |
| Schocken, D | 1 |
| Anderson, SA | 1 |
| DeMets, DL | 1 |
| Shakoor, A | 1 |
| Zahoor, M | 1 |
| Fadoo, Z | 1 |
| Rizvi, A | 1 |
| Quadri, F | 1 |
| Tipoo, FA | 1 |
| Khurshid, M | 1 |
| Sajjad, Z | 1 |
| Hasan, BS | 1 |
| Oudit, GY | 2 |
| Backx, PH | 2 |
| Singh, BK | 1 |
| Pillai, KK | 1 |
| Kohli, K | 1 |
| Haque, SE | 1 |
| Crowe, S | 1 |
| Bartfay, WJ | 1 |
| Shibasaki, Y | 1 |
| Nishiue, T | 1 |
| Masaki, H | 1 |
| Matsubara, H | 1 |
| Iwasaka, T | 1 |
| Sun, H | 1 |
| Trivieri, MG | 1 |
| Koch, SE | 1 |
| Dawood, F | 1 |
| Ackerley, C | 1 |
| Yazdanpanah, M | 1 |
| Wilson, GJ | 1 |
| Schwartz, A | 1 |
| Liu, PP | 1 |
| Watanabe, M | 2 |
| Kawaguchi, H | 1 |
| Onozuka, H | 1 |
| Mikami, T | 1 |
| Urasawa, K | 1 |
| Okamoto, H | 2 |
| Watanabe, S | 1 |
| Abe, K | 1 |
| Kitabatake, A | 2 |
| Sato, A | 1 |
| Hattori, Y | 1 |
| Tomioka, H | 1 |
| Fukao, M | 1 |
| Sakuma, I | 1 |
| Kanno, M | 1 |
| Urayama, A | 1 |
| Yamada, S | 1 |
| Hirano, K | 1 |
| Kimura, R | 1 |
| Watanabe, H | 1 |
| Ohashi, K | 1 |
| Loke, KE | 1 |
| Messina, EJ | 1 |
| Mital, S | 1 |
| Hintze, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study[NCT02065492] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Cardiomyopathies
| Article | Year |
|---|---|
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Cardiomyopathies; Child; Edema; Ferritins; H | 2023 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Blood Transfusion; Calcium Channel Blockers; Cardio | 2018 |
4 trials available for amlodipine and Cardiomyopathies
12 other studies available for amlodipine and Cardiomyopathies
| Article | Year |
|---|---|
Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy.
Topics: Aldosterone; Amlodipine; Animals; Biomarkers; Cardiomyopathies; Cat Diseases; Cats; Furosemide; Hype | 2022 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
Uncertain Etiology of Left Ventricular Hypertrophy in a Young Subject With Hypertension Treated With Dexamphetamine.
Topics: Adult; Amlodipine; Antihypertensive Agents; Cardiomyopathies; Deprescriptions; Dextroamphetamine; Ec | 2020 |
Effect of methylene blue treatment on amlodipine toxicity-induced myocardial depression.
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathies; Depression; Humans; Methylene Blue | 2022 |
Amlodipine Therapy for Iron-Overload Cardiomyopathy: The Enduring Value of Translational Research.
Topics: Amlodipine; Cardiomyopathies; Humans; Iron; Iron Overload; Translational Research, Biomedical | 2016 |
Isoproterenol-induced cardiomyopathy in rats: influence of Acorus calamus Linn.: A. calamus attenuates cardiomyopathy.
Topics: Acorus; Amlodipine; Animals; Antioxidants; Calcineurin; Cardiomyopathies; Catalase; Disease Models, | 2011 |
Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice.
Topics: Aldehydes; Amlodipine; Animals; Calcium Channel Blockers; Cardiomyopathies; Free Radicals; Hemochrom | 2002 |
L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy.
Topics: Amlodipine; Animals; Biological Transport; Calcium Channel Blockers; Calcium Channels; Cardiomyopath | 2003 |
Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Calcium; Calcium Channel | 1998 |
Effect of prolonged treatment with amlodipine on enhanced vascular contractility in cardiomyopathic hamsters.
Topics: Actin Cytoskeleton; Amlodipine; Angiotensin II; Animals; Aorta; Calcium; Cardiomyopathies; Cricetina | 1999 |
Improvement in the histopathology of hearts from cardiomyopathic BIO TO-2 hamsters following long-term administration of amlodipine and cilnidipine.
Topics: Amlodipine; Animals; Animals, Inbred Strains; Body Weight; Calcium Channel Blockers; Calcium Channel | 2000 |
Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Bradykinin; Cardiomyopat | 2000 |